Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroprotective Agents | 11 | 2022 | 956 | 3.120 |
Why?
|
| Intracranial Hemorrhages | 7 | 2021 | 810 | 1.970 |
Why?
|
| Reperfusion Injury | 6 | 2022 | 1043 | 1.160 |
Why?
|
| NF-E2-Related Factor 2 | 4 | 2021 | 382 | 1.070 |
Why?
|
| Blood-Brain Barrier | 4 | 2019 | 1028 | 0.830 |
Why?
|
| Iron Chelating Agents | 2 | 2020 | 141 | 0.820 |
Why?
|
| Brain Ischemia | 8 | 2022 | 3001 | 0.810 |
Why?
|
| Brain Injuries | 5 | 2021 | 2053 | 0.740 |
Why?
|
| Endothelial Cells | 9 | 2021 | 3582 | 0.720 |
Why?
|
| Pericytes | 3 | 2019 | 298 | 0.660 |
Why?
|
| Intracellular Space | 1 | 2019 | 198 | 0.600 |
Why?
|
| Oleanolic Acid | 1 | 2016 | 43 | 0.520 |
Why?
|
| Microvessels | 2 | 2017 | 586 | 0.520 |
Why?
|
| Infarction, Middle Cerebral Artery | 6 | 2024 | 484 | 0.510 |
Why?
|
| Oligopeptides | 2 | 2020 | 1195 | 0.490 |
Why?
|
| Antioxidants | 4 | 2022 | 1671 | 0.470 |
Why?
|
| Stroke | 8 | 2024 | 9744 | 0.470 |
Why?
|
| Tetrazoles | 2 | 2017 | 923 | 0.450 |
Why?
|
| Aniline Compounds | 1 | 2019 | 1079 | 0.450 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2023 | 1023 | 0.450 |
Why?
|
| Iron | 2 | 2020 | 1812 | 0.450 |
Why?
|
| Imidazoles | 1 | 2019 | 1168 | 0.430 |
Why?
|
| Disease Models, Animal | 17 | 2024 | 18329 | 0.380 |
Why?
|
| Cerebrovascular Circulation | 6 | 2023 | 2671 | 0.330 |
Why?
|
| Mitochondria | 3 | 2020 | 3678 | 0.290 |
Why?
|
| Warfarin | 1 | 2016 | 1493 | 0.280 |
Why?
|
| Triterpenes | 2 | 2018 | 78 | 0.280 |
Why?
|
| Cerebral Hemorrhage | 5 | 2023 | 2654 | 0.280 |
Why?
|
| Glucose | 3 | 2022 | 4340 | 0.270 |
Why?
|
| Mice | 24 | 2024 | 81898 | 0.270 |
Why?
|
| Carotenoids | 2 | 2020 | 620 | 0.260 |
Why?
|
| Oxygen | 2 | 2022 | 4252 | 0.260 |
Why?
|
| Reactive Oxygen Species | 5 | 2022 | 2144 | 0.250 |
Why?
|
| Animals | 30 | 2024 | 168939 | 0.240 |
Why?
|
| Brain | 10 | 2022 | 27158 | 0.240 |
Why?
|
| Behavior, Animal | 3 | 2021 | 1865 | 0.210 |
Why?
|
| Cyclodextrins | 1 | 2022 | 63 | 0.200 |
Why?
|
| Hemin | 2 | 2019 | 51 | 0.200 |
Why?
|
| Benzamidines | 1 | 2021 | 20 | 0.200 |
Why?
|
| Cell Death | 4 | 2020 | 1676 | 0.190 |
Why?
|
| Apoptosis | 6 | 2022 | 9514 | 0.190 |
Why?
|
| CADASIL | 1 | 2022 | 83 | 0.190 |
Why?
|
| Guanabenz | 1 | 2021 | 6 | 0.190 |
Why?
|
| Guanidines | 1 | 2021 | 194 | 0.180 |
Why?
|
| Brain Infarction | 2 | 2024 | 285 | 0.170 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2021 | 174 | 0.170 |
Why?
|
| Cells, Cultured | 5 | 2021 | 18986 | 0.170 |
Why?
|
| Anticoagulants | 1 | 2016 | 4854 | 0.170 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2020 | 236 | 0.170 |
Why?
|
| Cell Survival | 3 | 2021 | 5749 | 0.170 |
Why?
|
| Clonidine | 1 | 2021 | 170 | 0.170 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2021 | 92 | 0.170 |
Why?
|
| Ischemic Attack, Transient | 2 | 2023 | 874 | 0.170 |
Why?
|
| Collagenases | 2 | 2017 | 221 | 0.170 |
Why?
|
| Cortical Spreading Depression | 1 | 2023 | 288 | 0.170 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2019 | 9 | 0.170 |
Why?
|
| Hydrogen Peroxide | 2 | 2020 | 741 | 0.160 |
Why?
|
| Ferrous Compounds | 1 | 2019 | 40 | 0.160 |
Why?
|
| Reperfusion | 1 | 2020 | 268 | 0.160 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 213 | 0.150 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2017 | 293 | 0.150 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2019 | 204 | 0.150 |
Why?
|
| Hematoma | 2 | 2023 | 766 | 0.150 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2017 | 11 | 0.150 |
Why?
|
| Choroidal Neovascularization | 1 | 2021 | 364 | 0.140 |
Why?
|
| Collagen Type IV | 1 | 2017 | 125 | 0.140 |
Why?
|
| Eye | 1 | 2021 | 711 | 0.140 |
Why?
|
| Neurons, Afferent | 1 | 2019 | 498 | 0.130 |
Why?
|
| Random Allocation | 2 | 2017 | 2394 | 0.130 |
Why?
|
| Cerebral Infarction | 1 | 2020 | 968 | 0.120 |
Why?
|
| Capillary Permeability | 1 | 2019 | 772 | 0.120 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2017 | 685 | 0.120 |
Why?
|
| Eye Diseases | 1 | 2021 | 660 | 0.120 |
Why?
|
| Adiponectin | 1 | 2021 | 1121 | 0.120 |
Why?
|
| Hyperalgesia | 1 | 2019 | 527 | 0.120 |
Why?
|
| Neuroblastoma | 1 | 2022 | 1266 | 0.110 |
Why?
|
| Neurons | 3 | 2020 | 9515 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2021 | 1193 | 0.110 |
Why?
|
| Administration, Oral | 2 | 2020 | 4019 | 0.110 |
Why?
|
| Hemoglobins | 1 | 2019 | 1531 | 0.100 |
Why?
|
| Male | 20 | 2024 | 364154 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2021 | 1161 | 0.100 |
Why?
|
| Autophagy | 1 | 2020 | 1345 | 0.100 |
Why?
|
| Cytoskeleton | 1 | 2017 | 1179 | 0.100 |
Why?
|
| Mice, Inbred Strains | 3 | 2021 | 1767 | 0.100 |
Why?
|
| Hippocampus | 1 | 2024 | 3776 | 0.090 |
Why?
|
| Ischemia | 1 | 2020 | 1905 | 0.090 |
Why?
|
| Memory | 1 | 2021 | 2192 | 0.090 |
Why?
|
| Seizures | 1 | 2024 | 2996 | 0.090 |
Why?
|
| Cadherins | 1 | 2016 | 903 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 22351 | 0.090 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 849 | 0.090 |
Why?
|
| Endovascular Procedures | 2 | 2024 | 2215 | 0.090 |
Why?
|
| Anticonvulsants | 1 | 2020 | 1921 | 0.080 |
Why?
|
| Xanthophylls | 2 | 2020 | 95 | 0.080 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 1730 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2019 | 4424 | 0.080 |
Why?
|
| Cell Proliferation | 2 | 2021 | 10451 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2014 | 1121 | 0.070 |
Why?
|
| Humans | 17 | 2023 | 766812 | 0.070 |
Why?
|
| Blood Flow Velocity | 2 | 2021 | 1374 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 17089 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2270 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2020 | 3458 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2016 | 4033 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2016 | 10101 | 0.050 |
Why?
|
| Oxidative Stress | 3 | 2018 | 3139 | 0.050 |
Why?
|
| Rodentia | 1 | 2023 | 262 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2021 | 395 | 0.050 |
Why?
|
| Rats | 3 | 2023 | 23717 | 0.050 |
Why?
|
| Mice, Inbred ICR | 1 | 2020 | 361 | 0.040 |
Why?
|
| Laboratories | 1 | 2023 | 463 | 0.040 |
Why?
|
| Perfusion Imaging | 1 | 2021 | 193 | 0.040 |
Why?
|
| Papilledema | 1 | 2021 | 130 | 0.040 |
Why?
|
| Maze Learning | 1 | 2021 | 479 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 9101 | 0.040 |
Why?
|
| Thrombin | 1 | 2021 | 600 | 0.040 |
Why?
|
| Cell Movement | 2 | 2021 | 5204 | 0.040 |
Why?
|
| Larva | 1 | 2020 | 511 | 0.040 |
Why?
|
| Motor Activity | 2 | 2020 | 2711 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2021 | 633 | 0.040 |
Why?
|
| Protoporphyrins | 1 | 2018 | 167 | 0.040 |
Why?
|
| Retinal Neovascularization | 1 | 2021 | 287 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2021 | 1131 | 0.040 |
Why?
|
| Potassium | 1 | 2022 | 1314 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 1733 | 0.040 |
Why?
|
| Receptors, Notch | 1 | 2022 | 751 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2018 | 364 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2016 | 411 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2018 | 596 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2020 | 1562 | 0.030 |
Why?
|
| Nociceptors | 1 | 2019 | 460 | 0.030 |
Why?
|
| Organelle Shape | 1 | 2014 | 2 | 0.030 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2017 | 285 | 0.030 |
Why?
|
| Premedication | 1 | 2015 | 245 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2019 | 1887 | 0.030 |
Why?
|
| Retinal Vessels | 1 | 2021 | 863 | 0.030 |
Why?
|
| Time Factors | 3 | 2021 | 40149 | 0.030 |
Why?
|
| Protective Agents | 1 | 2015 | 150 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2017 | 706 | 0.030 |
Why?
|
| Neuroimmunomodulation | 1 | 2016 | 186 | 0.030 |
Why?
|
| Brain Edema | 1 | 2018 | 601 | 0.030 |
Why?
|
| Homeostasis | 1 | 2022 | 3343 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2022 | 5306 | 0.020 |
Why?
|
| Retina | 1 | 2021 | 2660 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2021 | 3511 | 0.020 |
Why?
|
| Gene Expression | 1 | 2021 | 7585 | 0.020 |
Why?
|
| Zebrafish | 1 | 2020 | 3035 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10745 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2016 | 2493 | 0.020 |
Why?
|
| Research Design | 1 | 2023 | 6206 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 8310 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2016 | 2978 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2014 | 1389 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 20146 | 0.020 |
Why?
|
| Cell Line | 1 | 2018 | 15564 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 15425 | 0.010 |
Why?
|
| Pain | 1 | 2019 | 5098 | 0.010 |
Why?
|
| Cognition | 1 | 2021 | 7057 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13642 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 11924 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2024 | 54872 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13644 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 30214 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 36570 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 23618 | 0.010 |
Why?
|
| Female | 2 | 2024 | 396532 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2021 | 65286 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 29959 | 0.010 |
Why?
|
| Aged | 1 | 2022 | 171344 | 0.000 |
Why?
|
Concepts
(170)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(19)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_